• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

诱导多能干细胞来源的 HLA 通用性血小板的生成和鉴定。

Generation and characterization of HLA-universal platelets derived from induced pluripotent stem cells.

机构信息

Doctor of Philosophy Program in Medical Sciences, Faculty of Medicine, Chulalongkorn University, Bangkok, 10330, Thailand.

Center of Excellence for Medical Genomics, Department of Pediatrics, Faculty of Medicine, Chulalongkorn University, Bangkok, 10330, Thailand.

出版信息

Sci Rep. 2020 May 21;10(1):8472. doi: 10.1038/s41598-020-65577-x.

DOI:10.1038/s41598-020-65577-x
PMID:32439978
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC7242456/
Abstract

Platelet demand has increased around the world. However, the inadequacy of donors, the risk of transfusion-transmitted infections and associated reactions, and the refractory nature of platelet transfusions are among the limitations of allogeneic platelet transfusions. To alleviate these problems, we propose generating platelets in a laboratory that do not induce alloimmunity to human leukocyte antigen (HLA) class I, which is a major cause of immune reaction in platelet transfusion refractoriness. Induced pluripotent stem cells (iPSCs) were generated from peripheral blood mononuclear cells (PBMCs) of a healthy Thai woman. We then knocked out the β2-microglobulin (β2m) gene in the cells using paired CRISPR/Cas9 nickases and sequentially differentiated the cells into haematopoietic stem cells (HSCs), megakaryocytes (MKs) and platelets. Silencing of HLA class I expression was observed on the cell surface of β2m-knockout iPSCs, iPSC-derived HSCs, MKs and platelets. The HLA-universal iPSC-derived platelets were shown to be activated, and they aggregated after stimulation. In addition, our in vivo platelet survival experiments demonstrated that human platelets were detectable at 2 and 24 hours after injecting the β2m-KO MKs. In summary, we successfully generated functional iPSC-derived platelets in vitro without HLA class I expression by knocking out the β2m gene using paired CRISPR/Cas9 nickases.

摘要

血小板的需求在全球范围内有所增加。然而,供体不足、输血传播感染和相关反应的风险以及血小板输注的难治性等问题限制了同种异体血小板输注的应用。为了解决这些问题,我们提出在实验室中生成不会引起人类白细胞抗原(HLA)I 类同种免疫的血小板,这是血小板输注抵抗中免疫反应的主要原因。我们从一名健康泰国女性的外周血单核细胞(PBMC)中生成诱导多能干细胞(iPSC)。然后,我们使用成对的 CRISPR/Cas9 切口酶在细胞中敲除β2-微球蛋白(β2m)基因,并依次将细胞分化为造血干细胞(HSCs)、巨核细胞(MKs)和血小板。我们观察到β2m 敲除 iPSC、iPSC 来源的 HSCs、MK 和血小板的细胞表面 HLA I 类表达沉默。敲除 HLA 通用的 iPSC 来源的血小板被证明具有激活作用,并在刺激后聚集。此外,我们的体内血小板存活实验表明,在注射β2m-KO MK 后 2 和 24 小时可检测到人类血小板。总之,我们成功地使用成对的 CRISPR/Cas9 切口酶敲除β2m 基因,在体外生成了无 HLA I 类表达的功能性 iPSC 来源的血小板。

相似文献

1
Generation and characterization of HLA-universal platelets derived from induced pluripotent stem cells.诱导多能干细胞来源的 HLA 通用性血小板的生成和鉴定。
Sci Rep. 2020 May 21;10(1):8472. doi: 10.1038/s41598-020-65577-x.
2
Scalable generation of universal platelets from human induced pluripotent stem cells.从人诱导多能干细胞中可扩展地生成通用血小板。
Stem Cell Reports. 2014 Nov 11;3(5):817-31. doi: 10.1016/j.stemcr.2014.09.010. Epub 2014 Oct 16.
3
iPSC-Derived Platelets Depleted of HLA Class I Are Inert to Anti-HLA Class I and Natural Killer Cell Immunity.iPSC 衍生血小板耗尽 HLA I 类是惰性的抗 HLA I 类和自然杀伤细胞免疫。
Stem Cell Reports. 2020 Jan 14;14(1):49-59. doi: 10.1016/j.stemcr.2019.11.011. Epub 2019 Dec 26.
4
Genetically engineered blood pharming: generation of HLA-universal platelets derived from CD34+ progenitor cells.基因工程血液制药:源自CD34+祖细胞的HLA通用血小板的生成
J Stem Cells. 2014;9(3):149-61.
5
HLA-universal platelet transfusions prevent platelet refractoriness in a mouse model.HLA通用型血小板输注可预防小鼠模型中的血小板输注无效。
Hum Gene Ther. 2013 Dec;24(12):1018-28. doi: 10.1089/hum.2013.074. Epub 2013 Nov 7.
6
Transient activation of c-MYC expression is critical for efficient platelet generation from human induced pluripotent stem cells.瞬时激活 c-MYC 表达对于从人诱导多能干细胞中有效生成血小板至关重要。
J Exp Med. 2010 Dec 20;207(13):2817-30. doi: 10.1084/jem.20100844. Epub 2010 Nov 22.
7
Selective Inhibition of ADAM17 Efficiently Mediates Glycoprotein Ibα Retention During Ex Vivo Generation of Human Induced Pluripotent Stem Cell-Derived Platelets.选择性抑制 ADAM17 在人诱导多能干细胞衍生血小板的体外生成过程中有效介导糖蛋白 Ibα 的保留。
Stem Cells Transl Med. 2017 Mar;6(3):720-730. doi: 10.5966/sctm.2016-0104. Epub 2016 Oct 5.
8
In vitro large scale production of megakaryocytes to functional platelets from human hematopoietic stem cells.从人造血干细胞体外大规模生产巨核细胞到功能血小板。
Biochem Biophys Res Commun. 2018 Oct 20;505(1):168-175. doi: 10.1016/j.bbrc.2018.09.090. Epub 2018 Sep 20.
9
Human Leukocyte Antigen Class I Pseudo-Homozygous Mesenchymal Stem Cells Derived from Human Induced Pluripotent Stem Cells.人白细胞抗原 I 类假纯合间充质干细胞来源于人诱导多能干细胞。
Stem Cell Rev Rep. 2020 Aug;16(4):792-808. doi: 10.1007/s12015-020-09990-9.
10
Generation of functional platelets from canine induced pluripotent stem cells.从犬诱导多能干细胞生成功能性血小板。
Stem Cells Dev. 2013 Jul 15;22(14):2026-35. doi: 10.1089/scd.2012.0701. Epub 2013 Mar 15.

引用本文的文献

1
Cell-based artificial platelet production: historical milestones, emerging trends, and future directions.基于细胞的人工血小板生产:历史里程碑、新兴趋势及未来方向。
Blood Res. 2025 May 27;60(1):32. doi: 10.1007/s44313-025-00071-9.
2
Status and prospects for the development of regenerative therapies for corneal and ocular diseases.角膜及眼部疾病再生疗法的发展现状与前景
Regen Ther. 2024 Sep 17;26:819-825. doi: 10.1016/j.reth.2024.09.001. eCollection 2024 Jun.
3
CRISPR-Cas9 immune-evasive hESCs are rejected following transplantation into immunocompetent mice.

本文引用的文献

1
Turbulence Activates Platelet Biogenesis to Enable Clinical Scale Ex Vivo Production.湍流激活血小板生成以实现临床规模的体外生产。
Cell. 2018 Jul 26;174(3):636-648.e18. doi: 10.1016/j.cell.2018.06.011. Epub 2018 Jul 12.
2
Repair of double-strand breaks induced by CRISPR-Cas9 leads to large deletions and complex rearrangements.CRISPR-Cas9 诱导的双链断裂的修复会导致大片段缺失和复杂重排。
Nat Biotechnol. 2018 Sep;36(8):765-771. doi: 10.1038/nbt.4192. Epub 2018 Jul 16.
3
Paired D10A Cas9 nickases are sometimes more efficient than individual nucleases for gene disruption.
CRISPR-Cas9免疫逃避的人胚胎干细胞在移植到具有免疫活性的小鼠体内后会被排斥。
Front Genome Ed. 2024 May 28;6:1403395. doi: 10.3389/fgeed.2024.1403395. eCollection 2024.
4
Mass production of iPSC-derived platelets toward the clinical application.诱导多能干细胞衍生血小板的大规模生产迈向临床应用。
Regen Ther. 2024 Jan 4;25:213-219. doi: 10.1016/j.reth.2023.12.009. eCollection 2024 Mar.
5
Haematopoietic development and HSC formation in vitro: promise and limitations of gastruloid models.体外造血发育和 HSC 形成:胚状体模型的前景与局限。
Emerg Top Life Sci. 2023 Dec 18;7(4):439-454. doi: 10.1042/ETLS20230091.
6
Immune-privileged tissues formed from immunologically cloaked mouse embryonic stem cells survive long term in allogeneic hosts.免疫豁免组织由免疫伪装的鼠胚胎干细胞形成,可在同种异体宿主中长期存活。
Nat Biomed Eng. 2024 Apr;8(4):427-442. doi: 10.1038/s41551-023-01133-y. Epub 2023 Nov 23.
7
Generating hematopoietic cells from human pluripotent stem cells: approaches, progress and challenges.从人类多能干细胞生成造血细胞:方法、进展与挑战。
Cell Regen. 2023 Sep 1;12(1):31. doi: 10.1186/s13619-023-00175-6.
8
LL-37 Triggers Antimicrobial Activity in Human Platelets.LL-37 激活人血小板的抗菌活性。
Int J Mol Sci. 2023 Feb 1;24(3):2816. doi: 10.3390/ijms24032816.
9
Engineered cord blood megakaryocytes evade killing by allogeneic T-cells for refractory thrombocytopenia.工程化脐血细胞巨核细胞逃避同种异体 T 细胞对难治性血小板减少症的杀伤作用。
Front Immunol. 2022 Sep 20;13:1018047. doi: 10.3389/fimmu.2022.1018047. eCollection 2022.
10
Engineering of immune checkpoints B7-H3 and CD155 enhances immune compatibility of MHC-I iPSCs for β cell replacement.工程化免疫检查点 B7-H3 和 CD155 增强了 MHC-I iPSCs 用于β细胞替代的免疫相容性。
Cell Rep. 2022 Sep 27;40(13):111423. doi: 10.1016/j.celrep.2022.111423.
成对的 D10A Cas9 切口酶有时比单个核酸酶更有效地用于基因破坏。
Nucleic Acids Res. 2018 Jul 6;46(12):e71. doi: 10.1093/nar/gky222.
4
CRISPR/Cas9 Genome-Editing System in Human Stem Cells: Current Status and Future Prospects.人类干细胞中的CRISPR/Cas9基因组编辑系统:现状与未来展望
Mol Ther Nucleic Acids. 2017 Dec 15;9:230-241. doi: 10.1016/j.omtn.2017.09.009. Epub 2017 Sep 30.
5
NK Cell Alloreactivity against KIR-Ligand-Mismatched HLA-Haploidentical Tissue Derived from HLA Haplotype-Homozygous iPSCs.自然杀伤细胞对 KIR 配体错配 HLA 单倍体组织的同种反应,该组织源自 HLA 单倍型纯合 iPSCs。
Stem Cell Reports. 2017 Sep 12;9(3):853-867. doi: 10.1016/j.stemcr.2017.07.020. Epub 2017 Aug 31.
6
HLA-E-expressing pluripotent stem cells escape allogeneic responses and lysis by NK cells.表达HLA-E的多能干细胞可逃避自然杀伤细胞的同种异体反应和裂解。
Nat Biotechnol. 2017 Aug;35(8):765-772. doi: 10.1038/nbt.3860. Epub 2017 May 15.
7
Platelets impair natural killer cell reactivity and function in endometriosis through multiple mechanisms.血小板通过多种机制损害子宫内膜异位症患者自然杀伤细胞的反应性和功能。
Hum Reprod. 2017 Apr 1;32(4):794-810. doi: 10.1093/humrep/dex014.
8
HLA Class I Depleted hESC as a Source of Hypoimmunogenic Cells for Tissue Engineering Applications.HLA I类缺失的人胚胎干细胞作为用于组织工程应用的低免疫原性细胞来源。
Tissue Eng Part A. 2015 Oct;21(19-20):2559-71. doi: 10.1089/ten.TEA.2015.0105. Epub 2015 Sep 10.
9
Platelet refractoriness--practical approaches and ongoing dilemmas in patient management.血小板抵抗性——患者管理中的实用方法和持续存在的困境。
Br J Haematol. 2015 Nov;171(3):297-305. doi: 10.1111/bjh.13597. Epub 2015 Jul 20.
10
Scalable generation of universal platelets from human induced pluripotent stem cells.从人诱导多能干细胞中可扩展地生成通用血小板。
Stem Cell Reports. 2014 Nov 11;3(5):817-31. doi: 10.1016/j.stemcr.2014.09.010. Epub 2014 Oct 16.